302 related articles for article (PubMed ID: 23242127)
1. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation.
Raevens S; De Pauw M; Reyntjens K; Geerts A; Verhelst X; Berrevoet F; Rogiers X; Troisi RI; Van Vlierberghe H; Colle I
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):495-502. PubMed ID: 23242127
[TBL] [Abstract][Full Text] [Related]
2. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension.
Sağ S; Yeşilbursa D; Güllülü S
Turk J Gastroenterol; 2014 Aug; 25(4):429-32. PubMed ID: 25254528
[TBL] [Abstract][Full Text] [Related]
3. Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension.
Hollatz TJ; Musat A; Westphal S; Decker C; D'Alessandro AM; Keevil J; Zhanhai L; Runo JR
Liver Transpl; 2012 Jun; 18(6):686-95. PubMed ID: 22315210
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension.
Cartin-Ceba R; Swanson K; Iyer V; Wiesner RH; Krowka MJ
Chest; 2011 Jan; 139(1):109-14. PubMed ID: 20705798
[TBL] [Abstract][Full Text] [Related]
5. Oral pulmonary vasoactive drugs achieve hemodynamic eligibility for liver transplantation in portopulmonary hypertension.
Legros L; Chabanne C; Camus C; Fournet M; Houssel-Debry P; Latournerie M; Jezequel C; Rayar M; Boudjema K; Guyader D; Bardou-Jacquet E
Dig Liver Dis; 2017 Mar; 49(3):301-307. PubMed ID: 27840058
[TBL] [Abstract][Full Text] [Related]
6. [Porto-pulmonary hypertension].
Chabot F; Gomez E; Boyer L; Kheir A; Le Pavec J; Sitbon O; Herve P
Rev Mal Respir; 2006 Dec; 23(6):629-41. PubMed ID: 17202968
[TBL] [Abstract][Full Text] [Related]
7. Portopulmonary hypertension.
Nayak RP; Li D; Matuschak GM
Curr Gastroenterol Rep; 2009 Feb; 11(1):56-63. PubMed ID: 19166660
[TBL] [Abstract][Full Text] [Related]
8. Secure Combination Therapy With Low-Dose Bosentan and Ambrisentan to Treat Portopulmonary Hypertension Minimizing Each Adverse Effect.
Muraoka H; Imamura T; Hatano M; Maki H; Yao A; Kinugawa K; Komuro I
Int Heart J; 2015; 56(4):471-3. PubMed ID: 26084462
[TBL] [Abstract][Full Text] [Related]
9. Portopulmonary hypertension: Still an appropriate consideration for liver transplantation?
Verma S; Hand F; Armstrong MJ; de Vos M; Thorburn D; Pan T; Klinck J; Westbrook RH; Auzinger G; Bathgate A; Masson S; Holt A; Houlihan DD; Ferguson JW
Liver Transpl; 2016 Dec; 22(12):1637-1642. PubMed ID: 27593213
[TBL] [Abstract][Full Text] [Related]
10. Portopulmonary hypertension.
Lv Y; Han G; Fan D
Scand J Gastroenterol; 2016 Jul; 51(7):795-806. PubMed ID: 27002212
[TBL] [Abstract][Full Text] [Related]
11. Current management approaches to portopulmonary hypertension.
Savale L; O'Callaghan DS; Magnier R; Le Pavec J; Hervé P; Jaïs X; Seferian A; Humbert M; Simonneau G; Sitbon O
Int J Clin Pract Suppl; 2011 Jan; (169):11-8. PubMed ID: 21176011
[TBL] [Abstract][Full Text] [Related]
12. Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience.
Awdish RL; Cajigas HR
Lung; 2013 Dec; 191(6):593-600. PubMed ID: 23979006
[TBL] [Abstract][Full Text] [Related]
13. The impact of treatment of portopulmonary hypertension on survival following liver transplantation.
Ashfaq M; Chinnakotla S; Rogers L; Ausloos K; Saadeh S; Klintmalm GB; Ramsay M; Davis GL
Am J Transplant; 2007 May; 7(5):1258-64. PubMed ID: 17286619
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological treatment of pulmonary hypertension at a turning point].
Watanabe H
Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):165-72. PubMed ID: 24717603
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension.
Austin MJ; McDougall NI; Wendon JA; Sizer E; Knisely AS; Rela M; Wilson C; Callender ME; O'Grady JG; Heneghan MA
Liver Transpl; 2008 Mar; 14(3):287-91. PubMed ID: 18306330
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of portopulmonary hypertension patients after liver transplantation.
Khaderi S; Khan R; Safdar Z; Stribling R; Vierling JM; Goss JA; Sussman NL
Liver Transpl; 2014 Jun; 20(6):724-7. PubMed ID: 24648168
[TBL] [Abstract][Full Text] [Related]
17. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series.
Sussman N; Kaza V; Barshes N; Stribling R; Goss J; O'Mahony C; Zhang E; Vierling J; Frost A
Am J Transplant; 2006 Sep; 6(9):2177-82. PubMed ID: 16796721
[TBL] [Abstract][Full Text] [Related]
18. Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Heresi GA; Love TE; Tonelli AR; Highland KB; Dweik RA
Am J Respir Crit Care Med; 2018 Oct; 198(8):1090-1093. PubMed ID: 29949380
[No Abstract] [Full Text] [Related]
19. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.
Halank M; Knudsen L; Seyfarth HJ; Ewert R; Wiedemann B; Kolditz M; Höffken G; Hoeper MM
Z Gastroenterol; 2011 Sep; 49(9):1258-62. PubMed ID: 21887662
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment.
Talwalkar JA; Swanson KL; Krowka MJ; Andrews JC; Kamath PS
Gastroenterology; 2011 Nov; 141(5):1673-9. PubMed ID: 21723219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
